CRISPR futures: Rethinking the politics of genome

New genome editing techniques such as CRISPR-Cas9 aspire to automate and standardize laboratory practices of genetic engineering at the molecular scale. They have been promoted as a ‘revolutionary’ means of production, which will revitalize industry, transform agribusiness and adapt it to changing climatic conditions. To realize this vision, a fundamental regulatory shift is now being enacted by multiple national governments around the world from Argentina to Canada, Brazil, Australia, South Africa, the United States, the United Kingdom, Japan, China and the European Union. As corporate science is directly in the service of private entities guided by a strict market rationality, while public research is increasingly pushed to prioritize immediate ‘industrial applications’ and the achievement of measurable ‘socio-economic impact’, genomic interventions are mostly geared towards expanding, accelerating and securing the accumulation of capital on a global scale. Structural market demands are embodied in gene-edited bodies produced for commercialization. While the emerging international regulatory regime for gene-edited organisms has been largely shaped by discussions focused on technical questions of health and safety, this tendency indicates the necessity of a wider democratic debate that would include the socio-economic, ethical and ecological concerns recently stressed by indigenous and peasant movements around the world. How will these new GM bodies transform the way people live and work in agricultural lands, industrial facilities, barnyards and slaughterhouses, in biotech labs and medical clinics? How will they affect lived ecologies? What types of multi-species worlds are being constructed through bioengineering practices, by whom and according to what political visions?